Go Deep
PharmaCorp Rx Inc.
PharmaCorp Rx Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,753 | -42.0 | 1.57 | 0.08 | 28.54 |
| Oct 2026 | 19,753 | -42.0 | 1.57 | 0.08 | 28.41 |
PharmaCorp Rx Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 7,728,164.0 | 7,188,412.0 | 7,689,580.0 | 4,802,259.0 |
| Net Profit | 30,257.0 | 108,202.0 | -852,383.0 | -427,516.0 |
| EPS | 0.0 | 0.0 | — | 0.0 |
PharmaCorp Rx Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 20,894,507.0 | 5,794,914.0 | 0.0 | 0.0 |
| Net Profit | -1,422,057.0 | -1,050,935.0 | -470,428.0 | -517,085.0 |
| EPS | -0.0 | -0.0 | -0.0 | -0.0 |
PharmaCorp Rx Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 65,570,283.0 | 35,209,042.0 | 2,320,511.0 | 2,733,379.0 | — |
| Total Liabilities | 13,300,357.0 | 4,642,778.0 | 46,185.0 | 16,465.0 | — |
| Total Equity | 51,921,980.0 | 30,343,781.0 | 2,274,326.0 | 2,716,914.0 | — |
PharmaCorp Rx Inc. Assets & Liabilities Breakdown (CAD millions)
What it owns — Dec 2025
Cash & short-term investments 39.5%Receivables 1.9%Inventory 4.1%Fixed assets (tangible) 8.4%Intangible assets 46.1%
How it's funded — Dec 2025
Short-term debt 0.6%Long-term debt 4.7%Payables 7.9%Other liabilities 7.0%Shareholders' equity 79.7%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 25.9 | 12.9 | 2.2 | 2.7 |
| Receivables | 1.2 | 0.3 | 0.0 | 0.0 |
| Inventory | 2.7 | 1.3 | 0.0 | 0.0 |
| Fixed assets (tangible) | 5.5 | 4.0 | 0.0 | 0.0 |
| Intangible assets | 30.2 | 16.6 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.1 | 0.0 | 0.1 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 0.4 | 0.1 | 0.0 | 0.0 |
| Long-term debt | 3.1 | 0.3 | 0.0 | 0.0 |
| Payables | 5.2 | 1.5 | 0.0 | 0.0 |
| Other liabilities | 4.6 | 2.7 | 0.0 | 0.0 |
| Shareholders' equity | 52.3 | 30.6 | 2.3 | 2.7 |
| Net tangible assets | 21.7 | 13.7 | 2.3 | 2.7 |
PharmaCorp Rx Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | 2,006,367.0 | 124,968.0 | -519,458.0 | -120,183.0 |
| Investing Activities | -13,717,485.0 | -16,864,331.0 | 0.0 | — |
| Financing Activities | 24,709,857.0 | 27,384,158.0 | 27,840.0 | 1,873,537.0 |